A short-term study on the new ADHD drug lisdexamfetamine was unsuitable for several reasons, mainly because the treatment was not conducted as part of a comprehensive treatment program, and no added benefit of the drug can be derived.

Source: Added benefit of lisdexamfetamine is not proven


David Cottle

UBB Owner & Administrator